– Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 18, 2017--
Inc. (NASDAQ:EXEL) announced today that its third quarter 2017
financial results will be released on Wednesday, November 1, 2017 after
the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call to discuss the results and provide a general
business update. The conference call will be accessible via the Internet
from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921
(international) and provide the conference call passcode 96645455 to
join by phone.
A telephone replay will be available until 8:00 p.m. EDT on November 3,
2017. Access numbers for the telephone replay are: 855-859-2056
(domestic) and 404-537-3406 (international); the passcode is 96645455. A
webcast replay will also be archived on www.exelixis.com
for one year.
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring them to patients
globally. With growing revenues from the three resulting commercialized
products – CABOMETYX®, COMETRIQ®, and COTELLIC®
– we are reinvesting in our business to maximize the potential of our
pipeline, which we intend to supplement with targeted business
development activities and internal drug discovery, all to deliver the
next generation of Exelixis medicines and help patients recover stronger
and live longer. For more information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018006466/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
Vice President, Public Affairs & Investor Relations